Abstract

<div>Abstract<p><b>Purpose:</b> To determine, by molecular imaging, how <i>in vivo</i> pharmacodynamics of estrogen-estrogen receptor (ER) binding differ between types of standard endocrine therapy.</p><p><b>Experimental Design:</b> The ER has been a highly successful target for breast cancer treatment. ER-directed treatments include lowering ligand concentration by using aromatase inhibitors (AI) and blocking the receptor with agents like tamoxifen (TAM) or fulvestrant (FUL). We measured regional estrogen-ER binding by using positron emission tomography with <sup>18</sup>F-fluoroestradiol (FES PET) prior to and during treatment with AI, TAM, or FUL in a series of 30 metastatic breast cancer patients. FES PET measured <i>in vivo</i> estrogen binding at all tumor sites in heavily pretreated women with metastatic bone soft tissue–dominant breast cancer. In patients with uterus (<i>n</i> = 16) changes in uterine FES uptake were also measured.</p><p><b>Results:</b> As expected, tumor FES uptake declined more markedly on ER blockers (TAM and FUL, average 54% decline) compared with a less than 15% average decline on estrogen-depleting AIs (<i>P</i> < 0.001). The rate of complete tumor blockade [FES standardized uptake value (SUV) ≤1.5] following TAM (5/5 patients) was greater than the blockade rate following FUL (4/11; 2-sided mid <i>P</i> = 0.019). Percent FES SUV change in the uterus showed a strong association with tumoral change (ρ = 0.63, <i>P</i> = 0.01).</p><p><b>Conclusions:</b> FES PET can assess the <i>in vivo</i> pharmacodynamics of ER-targeted agents and may give insight into the activity of established therapeutic agents. Imaging revealed significant differences between agents, including differences in the efficacy of blockade by different ER antagonists in current clinical use. <i>Clin Cancer Res; 17(14); 4799–805. ©2011 AACR</i>.</p></div>

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.